A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies, Inc · Obesity
Phase 2
Active, not recruiting
108
2025-03
Evidence dashboardStudies since 2006Updated Jul 31, 2026
Bremelanotide / PT-141Clinical Trials.
A source-linked view of every Bremelanotide / PT-141 study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 10
- Recruiting
- 0
- Completed
- 9
- Terminated
- 0
- Results posted
- 4
- Average enrollment
- 294
- Countries
- 4
- Highest phase
- Phase 4
Largest indexed study
723 participants · NCT02333071 →Developer / research origin
Palatin Technologies
Evidence summary
Activity is not efficacy.
Bremelanotide / PT-141 appears in 10 indexed studies: 0 recruiting, 9 completed and 4 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Bremelanotide / PT-141 is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
NCT IDStudyPhase / statusEnrollmentUpdated
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
Cosette Pharmaceuticals, Inc. · Lactating Mother
Phase 4
Completed
10
2026-01
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Kwang Dong Pharmaceutical co., ltd. · Hypoactive Sexual Desire Disorder
Phase 3
Completed
193
2024-11
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Palatin Technologies, Inc · Kidney Disease
Phase 2
Completed
16
2024-10
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Imperial College Healthcare NHS Trust · Hypoactive Sexual Desire Disorder
Phase 4
Completed
40
2024-08
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
AMAG Pharmaceuticals, Inc. · Nausea
Phase 1
Completed
228
2022-04
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder
Phase 3
Completed
723
2021-04
Showing 6 of 9 studies
No studies in this snapshot.
Full study index
Search Bremelanotide / PT-141 trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
10 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 18976696 ↗Arnow BA, Millheiser L, Garrett A, Lake Polan M, Glover GH, Hill KR, Lightbody A, Watson C, Banner L, Smart T, Buchanan T, Desmond JE. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience. 2009 Jan 23;158(2):484-502. doi: 10.1016/j.neuroscience.2008.09.044. Epub 2008 Oct 2.Linked from NCT04179734PMID 21718449 ↗Bianchi-Demicheli F, Cojan Y, Waber L, Recordon N, Vuilleumier P, Ortigue S. Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study. J Sex Med. 2011 Sep;8(9):2546-59. doi: 10.1111/j.1743-6109.2011.02376.x. Epub 2011 Jun 30.Linked from NCT04179734PMID 15226502 ↗Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10201-4. doi: 10.1073/pnas.0400491101. Epub 2004 Jun 28.Linked from NCT04179734PMID 18978095 ↗Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008 Nov;112(5):970-8. doi: 10.1097/AOG.0b013e3181898cdb.Linked from NCT04179734PMID 15193618 ↗Murphy K, Garavan H. An empirical investigation into the number of subjects required for an event-related fMRI study. Neuroimage. 2004 Jun;22(2):879-85. doi: 10.1016/j.neuroimage.2004.02.005.Linked from NCT04179734PMID 11023702 ↗Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, Skottner A. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000 Nov;42(5):393-420. doi: 10.1006/phrs.2000.0725.Linked from NCT04179734PMID 23830149 ↗Woodard TL, Nowak NT, Balon R, Tancer M, Diamond MP. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril. 2013 Oct;100(4):1068-76. doi: 10.1016/j.fertnstert.2013.05.041. Epub 2013 Jul 2.Linked from NCT04179734PMID 31599840 ↗Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500.Linked from NCT04179734
Related pages
Keep researching Bremelanotide / PT-141.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.